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Abstract
Background: Epidemiological studies have disclosed an independent effect of triglycerides on coronary heart
disease despite achievement of low-density lipoprotein cholesterol goals with statin therapy. Arterial stiffness has
been increasingly recognized as a strong predictor of cardiovascular disease and atherosclerotic disease. The
association between triglycerides and arterial stiffness is not well characterized. We aimed to determine the
relationship between triglycerides and arterial stiffness in a community-based longitudinal sample from Beijing,
China.
Methods: We related levels of plasma TGs to measures of arterial stiffness (carotid–femoral pulse wave velocity
[PWV] and carotid–radial PWV) in 1447 subjects (mean age, 61.3 years) from a community-based population in
Beijing, China.
Results: After a median follow-up interval of 4.8 years, multiple linear regression analysis revealed that TGs
were independently associated with carotid–femoral PWV (β = 0.747, P < 0.001) and carotid-radial PWV (β = 0.367,
P = 0.001). In the group older than 65 years, the association between baseline TG levels and follow-up carotid–
femoral PWV (β = 1.094, P = 0.001) and carotid-radial PWV (β = 0.524, P = 0.002) were strengthened. In forward
stepwise multivariate logistic regression analysis, every SD increase in TGδ was associated with a 1.296-increased
likelihood of the presence of carotid–femoral PWVδII (OR [per SD increase in TGδ]: 1.296; 95 % CI: 1.064 ~ 1.580;
P = 0.010) in Model 2, whereas the relationship between TGδ and carotid-radial PWVδII disappeared. In addition,
the relationship was strengthened between TGδ and the presence of carotid–femoral PWVδII (OR 1.526, 95 %
CI: 1.088–2.141, P = 0.014) in the group older than 65 years but not carotid-radial PWVδII. No association was noted
in subjects younger than 65 years.
Conclusions: Lower triglyceride levels were significantly associated with decreases in carotid–femoral PWV,
indicating that achieving low TG levels may be an additional therapeutic consideration in subjects with
atherosclerotic disease.
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Background
Patients with cardiometabolic abnormalities remain at
high risk of cardiovascular events when low-density lipo-
protein cholesterol (LDL-C) goals are obtained. This
residual risk is partially due to high TG levels despite
achievement of LDL-C goals with statin therapy. Epi-
demiological studies have disclosed an independent effect
of triglycerides (TGs) on coronary heart disease (CHD)
events in the presence of lower levels of high-density lipo-
protein cholesterol (HDL-C) [1, 2], higher levels of LDL-C
[1, 2] and T2DM [3, 4]. A decrease in initially elevated TG
levels was associated with a decrease in CHD risk com-
pared with stable high TG levels [5].
Arterial stiffness has been recognized as a strong pre-
dictor of subclinical vascular disease as well as cardio-
vascular mortality [6–9]. Great emphasis has been
placed on the role of arterial stiffness, which can be
noninvasively assessed via the measurement of pulse
wave velocity (PWV) [10, 11]. Carotid-femoral PWV is
the proven “gold standard” for arterial stiffness given the
largest amount of epidemiological evidence for its pre-
dictive value for CHD [12].
Whether arterial stiffening is associated with TGs in
subjects is not well established. The present study inves-
tigated the associations between TGs and measures of
arterial stiffness (carotid–femoral PWV and carotid–ra-
dial PWV) in a prospective community-dwelling popula-
tion. We hypothesize that TGs are a predictive factor for
arterial stiffness. In the present study, we examined the
relationship between TGs and arterial stiffness by inves-
tigating: (1) the predictive relationship of baseline TG
levels with follow-up arterial stiffness; and (2) the rela-
tionship between changes in TGs with changes in arterial




This paper analysed the association between TGs and ar-
terial stiffness (carotid-femoral PWV and carotid-radial
PWV) in a community-based cohort study of subjects
living in the Pingguoyuan area of Beijing, China. After a
routine health check-up between September 2007 and
January 2009, a total of 1680 subjects were initially eligible
for cross-sectional analysis. We prospectively followed this
community-based population for the first time from
February 1 to September 30, 2013. Complete follow-up
data were obtained from 1499 subjects (follow-up rate
89.2 %), and 181 participants were lost during the period
between the initiation of the study and the follow-up. No
differences other that baseline risk factors were noted in
those who completed baseline and follow-up assessments.
Of these, 52 were excluded from analyses because of
death; thus, 1447 participants were available for analysis.
The median follow-up interval for the original 1447 sub-
jects was 4.8 years. During these visits, all participants re-
ceived a questionnaire survey. Demographic information,
a medical history, blood pressure measurements, and an-
thropometric measurements were obtained. Fasting blood
and urine samples were also collected. The study was ap-
proved by the ethics committee of the People’s Liberation
Army General Hospital, and each subject provided in-
formed written consent.
Clinical data collection
Participants completed self-reporting standardized ques-
tionnaires about lifestyle factors, prevalent diseases, family
history, and medication use. Trained medical doctors eval-
uated anthropometrics. Height (cm) was measured using a
wall-mounted measuring tape, and weight (kg) was mea-
sured using a digital scale without shoes. Systolic and dia-
stolic blood pressures (SBP and DBP) were measured on
the right arm twice in a sitting position after 5 min of rest.
Biomarker variable determination
Blood samples were collected from participants after over-
night fast. Concentrations of fasting blood glucose (FBG),
total cholesterol (TC), TGs, HDL-C, LDL-C were measured
by the Roche enzymatic assays (Roche Diagnostics GmbH,
Mannheim, Germany) on a Roche autoanalyzer (Roche
Diagnostics, Indianapolis, IN, USA). All testing was per-
formed in the same laboratory by well trained personnel
following the criteria of the World Health Organization
Lipid Reference Laboratories.
Assessment of arterial stiffness
All subjects were asked to avoid smoking, alcohol and
caffeine for at least 12 h before performing the assessment.
Arterial stiffness was measured by automatic carotid-
femoral and carotid-radial PWV measurements using a
Complior SP device (Createch Industrie, France) after the
participants had rested for 5 to 10 min in a supine position,
in the morning, and at a stable temperature. PWV was
measured with two strain-gauge transducers along the ar-
tery. The procedure was performed using a TY-306 Fukuda
pressure-sensitive transducer (Fukuda Denshi Co, Japan)
that is fixed transcutaneously over the course of a pair of
arteries separated by a known distance; the carotid, femoral
and radial arteries (all on the right side) were used. One
transducer was positioned at the base of the neck over the
common carotid artery, and the other was positioned over
the femoral artery. PWV was calculated from the measure-
ment of the pulse transit time and the distance travelled by
the pulse between the two recording sites (measured on the
surface of the body in metres) according to the following
formula: PWV (m/s) = distance (m)/transit time (s) [13]. All
baseline and follow-up measurements were performed by
the same specific technicians.
Wang et al. Lipids in Health and Disease  (2016) 15:97 Page 2 of 9
Definition of variables
Smoking status was defined as smoking 1 or more ciga-
rettes per day for at least 1 year. Non-HDL-C levels were
calculated by the following equation: TG (mmol/L) -
HDL-C (mmol/L). Body mass index (BMI) was calculated
by the following equation: weight (kg)/height2 (m2).
Waist–hip ratio was calculated by the following equation:
waist circumference (cm)/hip circumference (cm). The
estimated glomerular filtration rate (eGFR) was calculated
using the following Chronic Kidney Disease Epidemiology
Collaboration equation: eGFR = 141 ×min (Scr/κ,1) α ×
max (Scr/κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if
black], where Scr is plasma creatinine (mg/dL), κ is 0.7 for
females and 0.9 for males, α is −0.329 for females and
−0.411 for males, min indicates the minimum of Scr/κ or
1, and max indicates the maximum of Scr/κ or 1. Hyper-
tension was defined as a mean SBP ≥140 mmHg, mean
DBP ≥90 mmHg, both, or the use of antihypertensive
medication. Diabetes mellitus (DM) was defined as a fast-
ing glucose ≥7.0 mmol/L, glucose ≥11.1 mmol/L at 2 h
after an oral 75 g glucose challenge, the use of antihyper-
glycaemic medication, or both.
Statistical analyses
The characteristics were expressed as the median (inter-
quartile range) or mean ± standard deviation (SD) for
continuous variables and percentages for dichotomous
variables. Follow-up carotid-femoral PWV was defined
as elevated (≥12 m/s) or normal level (<12 m/s) [8].
Differences in the baseline levels of risk factors and clin-
ical characteristics between subjects with elevated and
normal carotid-femoral PWV over 4.8 years of follow-up
were analysed using a t-test for continuous variables and
a chi-square test for categorical variables.
The Pearson correlation was used to describe the corre-
lations between the baseline TG level and follow-up arter-
ial stiffness. Multiple linear regression analysis were
performed to evaluate the associations between baseline
TG levels and follow-up arterial stiffness (dependent vari-
ables: carotid-femoral PWV or carotid-radial PWV as a
continuous variable; independent variables: age, gender,
hypertension, DM, current smoking, levels of plasma TGs,
non-HDL, LDL-C, SBP, DBP, FBG, BMI, weight, waist,
waist–hip ratio and eGFR). As necessary, TG levels and
other biomarkers were normalized by natural logarithm
transformation.
We investigated the association of change in TG levels
with the change in arterial stiffness (carotid-femoral PWVδI
vs. carotid-femoral PWVδII; carotid-radial PWVδI vs.
carotid-radial PWVδII) with logistic regression models. The
change in TG levels was expressed as TGδ (TGfollow-up-
TGbaseline). The change in arterial stiffness was expressed as
PWVδ (PWVfollow-up-PWVbaseline). PWVδ was categorized
as PWVδI (PWVfollow-up-PWVbaseline <0) and PWVδII
(PWVfollow-up-PWVbaseline ≥0). Forward stepwise multivari-
ate logistic regression analysis was performed to evaluate
odds ratios (OR) and 95 % confidence intervals (CI).
Regression models were adjusted for age and gender
(model 1) as well as hypertension, DM, current smoking,
change in TGs, change in non-HDL-C, change in LDL-C,
change in SBP, change in DBP, change in BMI, change in
weight, change in waist, change in waist–hip ratio and
change in eGFR (model 2).
Receiver operating characteristic (ROC) curves were
used to assess the ability of the baseline TG level indices
to predict arterial stiffness assessed by carotid-femoral
PWV and carotid-radial PWV.
All analyses were conducted using SPSS software for
Windows, version 13.0 (SPSS, Chicago, IL, USA). We
used Bonferroni correetion for multiple testing. P-values
<0.05 were considered statistically significant.
Results
Clinical characteristics of the subjects categorized by
gender
Altogether, we included 1447 subjects in the present
study. The baseline characteristics of the study popula-
tion according to carotid-femoral PWV groups (elevated
or normal) are summarized in Table 1. The mean age
(±SD) in the study was 61.30 ± 11.4 years. Older age,
male gender, hypertension, DM, CHD, current smoking,
higher SBP, higher waist, higher waist-hip ratio, higher
FBG, higher TG and LDL-C levels, and lower eGFR
levels were significantly associated with elevated carotid-
femoral PWV.
Association of baseline TG with follow-up arterial stiffness
Age (r = 0.528; P < 00.001), SBP (r = 0.325; P < 0.001),
Waist (r = 0.187; P < 0.001), waist –hip ratio (r = 0.084;
P = 0.002), FPG (r = 0.129; P < 0.001) and TGs (r =
0.093; P = 0.001, Fig. 1) were significantly and posi-
tively related to carotid-femoral PWV, but DBP (r =
−0.003; P = 0.904), weight (r = 0.007; P = 0.787), BMI
(r = 0.011; P = 0.687), TC (r = 0.020; P = 0.457) and (r =
0.033; P = 0.233) were not. Non-HDL-C (r = − 0.090; P =
0.001) and eGFR (r = −0.384; P < 0.001) were inversely
related to carotid-femoral PWV.
SBP (r = 0.102; P < 0.001), DBP (r = 0.209; P < 0.001),
weight (r = 0.171; P < 0.001), waist (r = 0.068; P = 0.016)
and TGs (r = 0.089; P < 0.001, Fig. 2) were significantly
and positively related to carotid-radial PWV, but age
(r = 0.168; P = 0.245), BMI (r = 0.032; P = 0.238), waist–
hip ratio (r = 0.082; P = 0.159), TC (r = 0.037; P = 0.180)
and LDL-C (r = 0.062; P = 0.0.025) were not. Non-HDL-C
(r = − 0.073 = 0.007) was inversely related to carotid-radial
PWV.
The association between baseline TGs as a continuous
variable (natural logarithm transformed) and follow-up
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arterial stiffness are summarized in Table 2. In multivari-
able linear regression analysis, baseline TG levels were
positively and independently associated with follow-up
carotid-femoral PWV (β = 0.747, P < 0.001) and carotid-
radial PWV (β = 0.367, P = 0.001), respectively. Further-
more, non-HDL-C, hypertension, diabetes (β = 0.623, P =
0.007), BMI and fasting blood glucose were positively and
independently associated with carotid-femoral PWV, older
age, LDL-C, SBP and weight; weakly associated with
follow-up carotid-femoral PWV, and eGFR; and negatively
associated with follow-up carotid-femoral PWV. Being
male (β = 0.456, P = 0.001) was positively associated with
follow-up carotid-radial PWV.
Subsequently, a subgroup analysis according to subject
age was conducted (Table 2). In the group older than
65 years, the association between baseline TG levels and
follow-up carotid-femoral PWV (β = 1.094, P = 0.001) and
carotid-radial PWV (β = 0.524, P = 0.002) in multivariable
linear regression analysis were strengthened. However, in
subjects younger than 65 years, none of the follow-up ar-
terial stiffness measures were significantly related to base-
line TG.
The receiver operating characteristic (ROC) curves for
assessing the TG level indices as predictors of arterial
stiffness assessed by carotid-femoral PWV and carotid-
radial PWV are presented in Figs. 3 and 4.
Table 1 Baseline characteristics of the subjects





(n = 1447) ≥12 (n = 571) <12 (n = 876)
Age 61.30 ± 11.4 65.59 ± 9.03 54.14 ± 10.11 <0.001
Male (%) 601 (41.53) 270 (47.28) 331 (37.78) <0.001
BMI 25.41 ± 3.32 25.41 ± 3.28 25.26 ± 4.17 0.583
SBP (mmHg) 128.7 ± 17.7 135.38 ± 18.37 124.37 ± 15.93 <0.001
DBP (mmHg) 77.11 ± 10.26 77.00 ± 10.92 77.18 ± 9.82 0.762
FBG (mmol/l) 5.39 ± 1.65 5.63 ± 1.87 5.21 ± 1.35 <0.001
TG (mmol/l) 1.80 ± 1.24 1.92 ± 1.27 1.74 ± 1.24 0.017
TC (mmol/l) 5.01 ± 0.93 5.02 ± 0.97 5.01 ± 0.89 0.845
HDL-C (mmol/l) 1.34 ± 0.42 1.30 ± 0.43 1.37 ± 0.41 0.247
LDL-C (mmol/l) 2.91 ± 0.71 2.96 ± 0.73 2.87 ± 0.69 0.030
Non-HDL-C
(mmol/l)
3.53 ± 1.09 3.54 ± 1.16 3.52 ± 1.06 0.730
Waist (cm) 86.45 ± 9.34 88.63 ± 9.12 85.02 ± 10.19 <0.001
Waist-hip ratio 0.87 ± 0.05 0.88 ± 0.06 0.86 ± 0.0.07 <0.001
eGFR (ml/min) 94.2 ± 14.30 88.18 ± 14.19 98.63 ± 12.45 <0.001
Smokers 380 (26.26) 175 (30.65) 205 (23.40) <0.001
Hypertension 755 (52.17) 418 (73.20) 337 (38.47) <0.001
New 143 (9.88) 62 (10.86) 81 (9.24) 0.360
Anti-drug 399 (52.85) 228 (54.54) 171 (50.74) 0.333
Diabetes 302 (20.87) 183 (24.22) 119 (18.45) <0.001
New 117 (8.09) 54 (9.46) 63 (7.19) 0.148
Anti-drug 126 (41.72) 85 (46.44) 41 (34.45) 0.038
CHD 175 (12.09) 106 (18.56) 69 (7.88) <0.001
New 94 (6.49) 45 (7.88) 49 (5.59) 0.084
BMI body mass index, SBP systolic blood, DBP diastolic blood pressure, FBG fast
blood glucose, TG triglyceride, TC total cholesterol, HDL-C high- density
lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, eGFR
estimated glome-rular filtration rate, CHD coronary heart disease, PWV
pulse-wave velocity
Fig. 1 Relation between TGs and cf-PWV. The Pearson’s correlation was
used to describe the relationships between TGs and cf-PWV. cf-PWV was
positive relationship with TGs in 1447 subjects. cf-PWV, carotid–femoral
pulse wave velocity; TGs, Triglycerides; X-axis: the value of TGs (mmol/L);
Y-axis: the value of cf-PWV (ms−1); r, coefficient of Pearson’s correlation;
P< 0.001 with statistical significance
Fig. 2 Relation between TGs and cr-PWV. The Pearson’s correlation was
used to describe the relationships between TGs and cr-PWV. cr-PWV was
positive relationship with TGs in 1447 subjects. cr-PWV, carotid–radial
pulse wave velocity; TGs, Triglycerides; X-axis: the value of TGs (mmol/L);
Y-axis: the value of cr-PWV (ms−1); r, coefficient of Pearson’s correlation;
P< 0.001 with statistical significance
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Effect of change in TG on change in arterial stiffness
The relationship between the change in the TG levels
(TGδ) and the change in the carotid-femoral PWV (ca-
rotid-femoral PWVδI vs. carotid-femoral PWVδII) is
presented in Table 3. The presence of carotid-femoral
PWVδII (OR 1.107, 95 % CI: 1.039 ~ 1.299, P = 0.012)
was significantly related to TGδ in the unadjusted
model. In the adjusted models (1 and 2), the association
of TGδ with carotid-femoral PWVδII remained statisti-
cally significant. Each SD increase in TGδ was associated
with a 1.296-increased likelihood of the presence of
carotid-femoral PWVδII (OR [per SD increase in TGδ]:
Table 2 Multiple linear regression analysis of baseline parameters and follow-up arterial stiffness
Carotid–femoral PWV Carotid–radial PWV
β CI P-value β CI P-value
All subjects (n = 1447)
Age 0.097 0.078 ~ 0.116 <0.001 −0.025 −0.037 ~ −0.012 <0.001
Male 0.253 0.180 ~ 0.686 0.252 0.456 0.179 ~ 0.734 <0.001
Smoking 0.081 −0.261 ~ 0.424 0.641 0.049 −0.170 ~ 0.269 0.659
Diabetes 0.623 0.171 ~ 1.076 0.007 0.232 0.058 ~ 0.522 0.117
Hypertension 0.444 0.083 ~ 0.805 0.016 0.018 0.014 ~ 0.149 0.881
TGa 0.747 0.394 ~ 1.100 <0.001 0.367 0.140 ~ 0.593 0.002
Non-HDL-C 1.672 0.629 ~ 2.715 0.002 0.173 0.062 ~ 0.409 0.149
LDL-C 0.453 0.001 ~ 0.905 0.049 0.020 −0.269 ~ 0.310 0.892
SBP 0.040 0.028 ~ 0.052 <0.001 0.007 0.001 ~ 0.014 0.074
DBP −0.041 −0.060 ~ −0.022 <0.001 0.012 0.001 ~ 0.024 0.047
Weight 0.037 0.006 ~ 0.068 0.021 0.005 −0.016 ~ 0.025 0.657
BMI 0.160 0.073 ~ 0.246 <0.001 0.055 0.002 ~ 0.109 0.058
Waist 0.011 0.024 ~ 0.047 0.521 0.005 0.008 ~ 0.038 0.621
Waist–hip ratio 1.876 0.946 ~ 3.698 0.140 0.331 0.038 ~ 1.169 0.790
FBG 0.127 0.021 ~ 0.234 0.019 0.051 −0.017 ~ 0.119 0.143
eGFRa −1.672 −2.715 ~ −0.629 0.002 0.084 −0.584 ~ 0.753 0.754
Subjects older than 65 years (n = 625)
Age 0.091 0.045 ~ 0.137 <0.001 −0.032 −0.056 ~ −0.008 0.009
Male 0.308 0.059 ~ 1.372 0.408 0.029 −0.354 ~ 0.413 0.881
Hypertension 0.409 −0.148 ~ 0.966 0.138 −0.020 −0.311 ~ 0.272 0.894
Diabetes 0.664 0.019 ~ 1.346 0.057 −0.158 −0.516 ~ 0.199 0.385
Smoking 0.097 −0.456 ~ 0.650 0.732 −0.068 −0.358 ~ 0.221 0.644
TGa 1.094 0.449 ~ 1.738 0.001 0.524 0.186 ~ 0.861 0.002
Non-HDL-C 1.166 −2.574 ~ 1.965 0.174 −0.202 −1.840 ~ 1.436 0.809
LDL-C 0.364 0.013 ~ 1.191 0.388 0.053 −0.380 ~ 0.486 0.810
SBP 0.042 0.025 ~ 0.059 <0.001 0.010 0.001 ~ 0.019 0.026
DBP −0.052 −0.082 ~ −0.023 0.001 0.001 −0.015 ~ 0.016 0.928
Weight 0.056 0.004 ~ 0.109 0.036 0.034 0.007 ~ 0.062 0.002
BMI 0.249 0.103 ~ 0.394 0.001 0.123 0.047 ~ 0.200 0.002
Waist 0.039 0.020 ~ 0.079 0.507 0.002 −0.027 ~ 0.035 0.779
Waist–hip ratio 1.745 0.035 ~ 3.004 0.066 1.022 −1.988 ~ 4.561 0.541
FBG 0.148 −0.045 ~ 0.341 0.132 0.074 −0.712 ~ 0.860 0.853
eGFRa −1.323 −2.631 ~ 0.242 0.083 0.063 −0.712 ~ 0.869 0.847
TG triglyceride, non-HDL-C non-high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SBP systolic blood pressure, DBP diastolic blood
pressure, BMI body mass index, FBG fast blood glucose, eGFR estimated glomerular filtration rate, PWV pulse wave velocity
a: natural logarithm transformed
§: Covariates in the multiple-adjusted models included age, gender, hypertension, DM, current smoking, levels of plasma TG、non-HDL-C、LDL-C, SBP, DBP,FBG,
BMI, weight, Waist, Waist–hip ratio and eGFR
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1.296; 95 % CI: 1.064 ~ 1.580; P = 0.010) (Model 2,
Table 3). In addition, the relationship was strengthened
between TGδ and the presence of carotid-femoral
PWVδII (OR 1.526, 95 % CI: 1.088–2.141, P = 0.014) in
the group older than 65 years (Model 2) but not for
carotid-radial PWVδII. No association was noted in sub-
jects younger than 65 years.
Discussion
This is the first study to observe the relationship between
levels of TGs and carotid-femoral PWV in a community-
based prospective sample. In the present longitudinal
study, we found an association between baseline TGs and
follow-up arterial stiffness independent of age, gender and
other vascular risk factors, primarily in the oldest subjects.
We also identified an association between the change in
TGs and the change in carotid-femoral PWV, which indi-
cates that achieving low TG levels may be an additional
therapeutic consideration in subjects with atherosclerotic
disease.
Several large statin trials and meta-analyses have dem-
onstrated a reduction in LDL-C and cardiovascular mor-
bidity and mortality. Some trials have also highlighted the
significance of residual cardiovascular risk after treatment
of LDL-C to target levels. Even at the LDL-C goal, patients
with cardiometabolic abnormalities remain at high risk of
cardiovascular events. This residual risk is partially due to
high TG levels despite achievement of LDL–C goals with
statin therapy. Evidence from prospective studies of the
TG association supports a stronger association with CVD
risk in people with lower levels of HDL-C [1, 2], higher
LDL-C [1, 2] and T2DM [3, 4]. In addition, few studies
have reported the association of TG levels with arterial
stiffness, and the results were controversial. Henna et al.
found an association between TG and arterial stiffness
index in non-pregnant women even after adjustment for
HDL-C and other risk factors [14]. Recently, a study [15]
including 537 subjects found that TG levels were signifi-
cantly associated with arterial stiffness as measured by
brachial-ankle PWV in both genders. Dabelea et al. did
not identify a significant relationship between baseline TG
levels and arterial stiffness as measured by PWV over
Fig. 3 Receiver operating characteristic (ROC) curves of baseline TGs
indices to predict cf- PWV. ROC analysis was performed to
determine the sensitivity and specificity of the value of the area
under the curve (AUC)
Fig. 4 Receiver operating characteristic (ROC) curves of baseline TGs
indices to predict cr- PWV. ROC analysis was performed to
determine the sensitivity and specificity of the value of the area
under the curve (AUC)
Table 3 Logistic regression analysis for the association between




OR 95 % CI P Value
All subjects (n = 1447)
Unadjusted 1.107 1.039 ~ 1.299 0.012
Model 1 1.180 1.041 ~ 1.396 0.033
Model 2 1.296 1.064 ~ 1.580 0.010
Subjects older than 65 years (n = 625)
Unadjusted 1.312 1.057 ~ 1.745 0.002
Model 1 1.409 1.045 ~ 1.899 0.025
Model 2 1.526 1.088 ~ 2.141 0.014
TG triglyceride, TGδ change in TG, PWV pulse wave velocity, PWVδII
PWVfollow-up-PWVbaseline ≥ 0, OR odds ratio, CI confidence interval
model 1: age and gender
model 2: age, gender, hypertension, DM, current smoking, baseline
carotid-femoral PWV, change in TG, change in non-HDL-C, change in LDL-C,
change in SBP, change in DBP, change in BMI, change in weight, change in
Waist, change in Waist–hip ratio and change in eGFR
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time, whereas they reported that an increase in TG levels
of 48 mg/dL resulted in a 1.0 % increased PWV (P =
0.0483) [16].
The discrepancies among previous studies can be attrib-
uted to the following factors. First, the study subjects were
different. The present study (the average TG level was
1.80 ± 1.24 mmol/L) was based on a community sample in
which selection biases were inherently low, unlike previ-
ous studies that selected subjects with metabolic syn-
drome or diabetes [15, 16]. Second, our study population
is relatively old, with approximately half of the subjects
being ≥65 years of age. The steepest rise of transmural
pressure-induced arterial wall damage occurs after the age
of 60 years [17–19], leading to the strengthening of ill
effects by other risk factors in older subjects. In addition,
elderly subjects had an increased presence of other vascu-
lar risk factors, which may increase the susceptibility to
the influence of arterial stiffness via interaction with TGs
[20]. Third, the measurement of arterial stiffness was dif-
ferent. Arterial stiffness was measured by brachial-ankle
PWV in previous studies and response of central and
peripheral carotid-femoral PWV, which has no predictive
value in patients with end-stage renal disease (ESRD) [21].
In the present study, arterial stiffness was assessed via the
measurement of carotid-femoral PWV, which is a direct
measurement of the central artery with the largest amount
of epidemiological evidence for its predictive value of CV
events [9]. Fourth, the present study repeatedly measured
risk factors (e.g., TGs) and each participant’s outcome
(e.g., arterial stiffness) that would change with time, unlike
previous studies based on cross-sectional design, which
could not determine whether TGs are a predictive factor
for arterial stiffness.
The main finding of this study was that a higher level
of TGs was an independent predictor of carotid-femoral
PWV. Several potential mechanisms support TGs as a
biomarker of carotid-femoral PWV risk given the role of
TG-rich lipoproteins. Following the hydrolysis of exogen-
ously derived chylomicrons or endogenously secreted very-
low-density lipoproteins, cholesterol-enriched remnant by-
products enter the subendothelial space [22]. Indirectly,
elevated TGs impairs the capacity of high density lipopro-
tein to deliver cholesteryl esters, which may promote ath-
erosclerosis via the scavenger receptor class B Type I (SR-
BI) [23]. Moreover, cross-sectional studies [24–27] found
that enhanced arterial stiffness in hypertriglyceridaemic
states might be partly attributed to triglyceride-related LDL
atherogenicity, such as small, dense LDL particles and oxi-
dative modification of LDL. Hypertriglyceridemia-induced
proinflammatory and oxidative milieu may further enhance
adhesion molecule expression, increase foam cell forma-
tion, and increase the toxicity of smooth muscle [28, 29].
Hypertriglyceridemia also stimulates the release and/or
expression of endothelial mediators in vitro, such as
endothelin-1, which significantly promotes endothelial dys-
function, a critical early step in the development of arterio-
sclerosis [30–32].
Additionally, we found that change in TGs was associ-
ated with change in carotid-femoral PWV among subjects,
indicating that lower plasma TG levels were associated
with decreases in carotid-femoral PWV. The result was
consistent with those reported by previous studies. As pre-
viously shown, decreased TG levels were independently
associated with a reduced risk of CHD events compared
with stable high triglyceride levels [33]. Moreover, in the
PROVE IT-TIMI 22 trial, on-treatment TGs <150 mg/dl
dramatically affects CHD events after adjustment of LDL-
C levels [22]. These data lend support to the concept that
achieving low TG levels may be an additional therapeutic
consideration in subjects with atherosclerotic disease.
Furthermore, we also observed that change in TGs was
positively associated with change in carotid-femoral PWV
but not with change in carotid-radial PWV. This effect
may be attributed to the different morphology, material
properties, and mechanical behaviour of the arterial wall
[34–36]. In an experimental study of minipigs, athero-
sclerotic lesions were structurally heterogeneous, aniso-
tropic, and incompressible [37]. All of these results can be
explained by the theory that the composition of arterial
wall material (smooth muscle cells and extracellular
matrix, mainly collagenous tissue) is a strong determinant
of PWV and extent of atherosclerosis [38].
In this study, we also found that age, hypertension, dia-
betes, non-HDL-C, FBG and BMI were positively and in-
dependently associated with carotid-femoral PWV. These
results are consistent with those reported by previous
studies [39]. The association between BMI and carotid-
femoral PWV can be attributed to the following factors.
First, insulin resistance, which accompanies abdominal
obesity, has vascular effects through associated hyperinsu-
linaemia and increased glycaemia [40, 41]. Second, ab-
dominal obesity might contribute to carotid-femoral PWV
through inflammation [42].
The present study has limitations. First, a significant
proportion of subjects (181, 10.7 %) were excluded due to
loss to follow-up. This loss is a well-known and unavoid-
able limitation of epidemiological studies, which may be
biased towards the null hypothesis. Second, the present
study was based on subjects from Beijing communities;
therefore, the conclusions may not represent Chinese
individuals from other ethnic groups.
Conclusion
Lower triglyceride levels were significantly associated
with decreases in carotid–femoral PWV, indicating that
achieving low TG levels may be an additional thera-
peutic consideration in subjects with atherosclerotic
disease.
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